Therapeutic potential of Garcinia cambogia and Emblica officinalis in the management of obesity and lipid profiles in a rat model of diet induced obesity

Ritu Yadav; Harleen K. Bindra; Rakesh C. Chaurasia

doi:10.18203/2319-2003.ijbcp20242423

Authors

Ritu Yadav Department of Pharmacology, Moti Lal Nehru Medical College, Prayagraj, Uttar Pradesh, India
Harleen K. Bindra Department of Pharmacology, Moti Lal Nehru Medical College, Prayagraj, Uttar Pradesh, India
Rakesh C. Chaurasia Department of Pharmacology, Moti Lal Nehru Medical College, Prayagraj, Uttar Pradesh, India

DOI:

https://doi.org/10.18203/2319-2003.ijbcp20242423

Keywords:

Anti-obesity agents, Hypolipidemic, High energy diet, Natural remedies for obesity

Abstract

Background: Obesity has emerged as one of the significant public health burdens across the globe, which predisposes the risk of cardiovascular diseases and metabolic dysfunctions. Medicinal plants can be possible therapeutic measures for managing obesity. Garcinia cambogia and E. officinalis have been used for their anti-obesity and hypolipidemic properties. The objective of this study was to evaluate and compare the anti-obesity and hypolipidemic effects of Garcinia cambogia and E. officinalis in a high energy diet-induced obese rat model.

Methods: A total 36 albino rats were included in the study. The animals were randomly divided into 6 groups of 6 rats each. Group 1 (control) received distilled water orally, Group 2 received Garcinia cambogia extract orally in dose of 200 mg/kg/day, Group 3 received Garcinia cambogia extract orally in dose of 400 mg/kg/day, Group 4 received E. officinalis extract orally in dose of 20 mg/kg/day, Group 5 received E. officinalis extract orally in dose of 40 mg/kg/day and Group 6 (standard) received Orlistat in dose 20 mg/kg/day. Parameters assessed included body weight and lipid profile (total cholesterol, triglycerides, LDL cholesterol, and HDL cholesterol).

Results: Both Garcinia cambogia and Emblica officinalis interventions demonstrated significant reductions in body weight gain and improvements in lipid profile compared to the HED group. The intervention groups exhibited notable decreases in total cholesterol, triglycerides, and LDL cholesterol levels, along with an increase in HDL cholesterol levels.

Conclusions: Our findings suggest that Garcinia cambogia and Emblica officinalis possess anti-obesity and hypolipidemic effects in a high energy diet-induced obese rat model. These naturals show promise as potential therapeutic agents for combating obesity and associated dyslipidemia. Further research is needed to understand and validate their efficacy in human populations.

Metrics

Metrics Loading ...

References

Obesity and overweight. 2024. Available at https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight. Accessed on 12th January 2024.

James PT, Leach R, Kalamara E, Shayeghi M. The worldwide obesity epidemic. Obesity research. 2001;9(S11):228-33.

Guh DP, Zhang W, Bansback N, Amarsi Z, Birmingham CL, Anis AH. The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis. BMC public health. 2009;9:1-20.

Bray GA, Ryan DH. Update on obesity pharmacotherapy. Ann N Y Acad Sci. 2014;1311:1-13.

Astell KJ, Mathai ML, Su XQ. A review on botanical species and chemical compounds with appetite suppressing properties for body weight control. Plant foods for human nutrition. 2013;68:213-21.

Yun JW. Possible anti-obesity therapeutics from nature–A review. Phytochemistry. 2010;71(14-15):1625-41.

World Obesity Atlas 2023. World Obesity Federation. World Obesity Federation n.d. Available at https://www.worldobesity.org/resources/resource-library/world-obesity-atlas-2023. Accessed on 12th January 2024.

Tak YJ, Lee SY. Anti-obesity drugs: long-term efficacy and safety: an updated review. The world journal of men's health. 2021;39(2):208.

Abdel-Sattar E, El Zalabani SM, Salama MM. Herbal and microbial products for the management of obesity. Anti-obesity drug discovery and development. 2014;2:130-210.

Shaik Mohamed Sayed UF, Moshawih S, Goh HP, Kifli N, Gupta G, Singh SK, Chellappan DK, Dua K, Hermansyah A, Ser HL, Ming LC. Natural products as novel anti-obesity agents: Insights into mechanisms of action and potential for therapeutic management. Frontiers in pharmacology. 2023;14:1182937.

Semwal RB, Semwal DK, Vermaak I, Viljoen A. A comprehensive scientific overview of Garcinia cambogia. Fitoterapia. 2015;102:134-48.

Nazish I, Ansari SH. Emblica officinalis–Anti-obesity activity. Journal of Complementary and Integrative Medicine. 2018;15(2):20160051.

Onakpoya I, Hung SK, Perry R, Wider B, Ernst E. The use of Garcinia extract (hydroxycitric acid) as a weight loss supplement: a systematic review and meta‐analysis of randomised clinical trials. Journal of obesity. 2011;(1):509038.

Vasques CA, Schneider R, Klein‐Júnior LC, Falavigna A, Piazza I, Rossetto S. Hypolipemic effect of Garcinia cambogia in obese women. Phytotherapy Research. 2014;28(6):887-91.

Hu J, Komakula A, Fraser ME. Binding of hydroxycitrate to human ATP-citrate lyase. Acta Crystallographica Section D: Structural Biology. 2017;73(8):660-71.

Kapoor MP, Suzuki K, Derek T, Ozeki M, Okubo T. Clinical evaluation of Emblica Officinalis Gatertn (Amla) in healthy human subjects: Health benefits and safety results from a randomized, double-blind, crossover placebo-controlled study. Contemporary clinical trials communications. 2020;17:100499.

Variya BC, Bakrania AK, Chen Y, Han J, Patel SS. Suppression of abdominal fat and anti-hyperlipidemic potential of Emblica officinalis: Upregulation of PPARs and identification of active moiety. Biomedicine and Pharmacotherapy. 2018;108:1274-81.

Chuah LO, Ho WY, Beh BK, Yeap SK. Updates on antiobesity effect of Garcinia origin (−)‐HCA. Evidence‐Based Complementary and Alternative Medicine. 2013;(1):751658.

Jeevangi S, Manjunath S, Sakhare PM. A study of anti-hyperlipidemia, hypolipedimic and anti-atherogenic activity of fruit of Emblica officinalis (amla) in high fat fed albino rats. IJMRHS. 2013;2(1):70-7.

Uygun A, Kadayifci A, Yesilova Z, Erdil A, Yaman H, Saka M et al. Serum leptin levels in patients with nonalcoholic steatohepatitis. ACG. 2000;95(12):3584-9.